ROC Analysis Identifies Baseline and Dynamic NLR and dNLR Cut-Offs to Predict ICI Outcome in 402 Advanced NSCLC Patients
Journal of Molecular Pathology · 2020
DOI: 10.3390/jmp1010004 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Molecular Pathology, 2020. Verfasst von Simona Carnio und 18 weiteren Autor:innen. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 28 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
Neutrophil-to-Lymphocyte Ratio (NLR) and derived Neutrophils-to-(Leukocytes minus neutrophils) Ratio (dNLR) have been proposed as possible biomarkers of response to immune checkpoint inhibitors (ICI). However, in non-small cell lung cancer (NSCLC) studies, various NLR and/or dNLR cut-offs have been used, manly based on previous reports on melanoma.
Methods
In this Italian multicenter retrospective study, NLR, dNLR, platelet-to-lymphocyte ratio, albumin, and lactate dehydrogenase (LDH) were longitudinally assessed in patients with stage IV non-small cell lung cancer (NSCLC) treated with ICI. The primary objective was to evaluate if baseline parameters predicted response to ICI, using Receiver Operating Characteristic (ROC) curves. Secondary endpoint was to evaluate if dynamic changing of NLR and dNLR also predicted response.
Results
Data of 402 patients were collected and analyzed. Among the baseline parameters considered, NLR and dNLR were the most appropriate biomarkers according to the ROC analyses, which also identified meaningful cut-offs (NLR = 2.46; dNLR = 1.61). Patients with low ratios reported a significantly improved outcome, in terms of overall survival (p = 0.0003 for NLR; p = 0.0002 for dNLR) and progression free survival (p = 0.0004 for NLR; p = 0.005 for dNLR). The role of NLR and dNLR as independent biomarkers of response was confirmed in the Cox regression model. When assessing NLR and dNLR dynamics from baseline to cycle 3, a decrease ≥1.04 for NLR and ≥0.41 for dNLR also predicted response. Conclusions in our cohort, we confirmed that NLR and dNLR, easily assessable on peripheral blood, can predict response at baseline and early after ICI initiation. For both baseline and dynamic assessment, we identified clinically meaningful cut-offs, using ROC curves.
Zitieren
APA
Carnio, S., Mariniello, A., Pizzutilo, P., Numico, G., Borra, G., Lunghi, A., Parra, H. S., Buosi, R., Vavalà, T., Stura, I., Genestroni, S., Alemanni, A., Arizio, F., Catino, A., Montrone, M., Tabbò, F., Galetta, D., Migliaretti, G., & Novello, S. (2020). ROC Analysis Identifies Baseline and Dynamic NLR and dNLR Cut-Offs to Predict ICI Outcome in 402 Advanced NSCLC Patients. Journal of Molecular Pathology. https://doi.org/10.3390/jmp1010004
Vancouver
Carnio S, Mariniello A, Pizzutilo P, Numico G, Borra G, Lunghi A, et al. ROC Analysis Identifies Baseline and Dynamic NLR and dNLR Cut-Offs to Predict ICI Outcome in 402 Advanced NSCLC Patients. Journal of Molecular Pathology. 2020. doi:10.3390/jmp1010004
BibTeX
@article{Carnio2020,
author = {Carnio, Simona and Mariniello, Annapaola and Pizzutilo, Pamela and Numico, Gianmauro and Borra, Gloria and Lunghi, Alice and Parra, Hector Soto and Buosi, Roberta and Vavalà, Tiziana and Stura, Ilaria and Genestroni, Silvia and Alemanni, Alessandra and Arizio, Francesca and Catino, Annamaria and Montrone, Michele and Tabbò, Fabrizio and Galetta, Domenico and Migliaretti, Giuseppe and Novello, Silvia},
title = {ROC Analysis Identifies Baseline and Dynamic NLR and dNLR Cut-Offs to Predict ICI Outcome in 402 Advanced NSCLC Patients},
journal = {Journal of Molecular Pathology},
year = {2020},
doi = {10.3390/jmp1010004}
}
EUVIMED